EUCTR2004-001558-10-ES进行中（未招募）1 期
BEACOPP (4 ciclos escalado + 4 ciclos basal) vs ABDV (8 ciclos) en el linfoma de Hodgkin en estadios III-IV. - EORTC 20012
HOSPITAL DE LA SANTA CREU I SANT PA0 个研究点目标入组 0 人开始时间: 2004年9月21日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Edad 16-60 años, enfermedad de Hodgkin documentada histologicamente, estadio clinico III-IV, presencia de al menos una lesion mesurable.
- •Are the trial subjects under 18?
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years)
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Tratamiento previo de Enfermedad de Hodgkin, pacientes embarazadas, infeccion activa grave.
研究者
相似试验
进行中（未招募）
不适用
BEACOPP (4 cycles escalated + 4 cycles baseline) versus ABVD (8 cycles) in stage III & IV Hodgkin’s lymphomaHodgkin's LymphomaMedDRA version: 8.1Level: HLGTClassification code 10025319Term: Lymphomas Hodgkin's diseaseEUCTR2004-001558-10-CZEuropean Organisation for Research and Treatment of Cancer550
进行中（未招募）
1 期
BEACOPP (4 cycles escalated + 4 cycles baseline) versus ABVD (8 cycles) in stage III & IV Hodgkin’s lymphomaHodgkin's LymphomaMedDRA version: 8.1Level: HLGTClassification code 10025319Term: Lymphomas Hodgkin's diseaseEUCTR2004-001558-10-PLEuropean Organisation for Research and Treatment of Cancer550
进行中（未招募）
不适用
Comparison of the Effects Noted in The ApoB/ApoA-I ratio Using Rosuvastatin and atorvastatin in patients with acUte coronary Syndrome. - CENTAURUSEUCTR2005-002892-34-IEAstraZeneca SAS1,150
进行中（未招募）
不适用
Comparison of the Effects Noted in The ApoB/ApoA-I ratio Using Rosuvastatin and atorvastatin in patients with acUte coronary Syndrome. - CENTAURUSMen or women who are =18 years old diagnosed with non ST elevation - acute coronary syndrome (NSTE-ACS) and onset of clinical symptoms less than 48 hours at the admission for which a PCI is planned or anticipated. Patients with STEMI and primary PCI planned within 24 hours of admission will not be included. Patients will not be allowed to have taken any cholesterol-lowering medications during 1 month prior to enrolment.EUCTR2005-002892-34-GRAstraZeneca SAS1,150
进行中（未招募）
不适用
Comparison of the Effects Noted in The ApoB/ApoA-I ratio Using Rosuvastatin and atorvastatin in patients with acUte coronary Syndrome. - CENTAURUSMen or women who are >18 and <75 years old diagnosed with non ST elevation - acute coronary syndrome (NSTE-ACS) and onset of clinical symptoms less than 24 hours at the admission for which a PCI is planned or anticipated. Patients with STEMI and primary PCI planned within 24 hours of admission will not be included. Patients will not be allowed to have taken any cholesterol-lowering medications during 1 month prior to enrolment.EUCTR2005-002892-34-PTAstraZeneca SAS1,150